A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults

Summary

Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was skipped due to changes in the overall clinical development plan. The conducted Part A was a dose-finding part to investigate the optimal dose, allowing dose adjustments upwards and downwards in younger participants. Doses tested in older participants were chosen based on acceptability of dosing in younger participants.

Timeline

Start

2020-09-09

Primary completion

2021-03-12

Completion

2022-02-07

Publications

• Vogel AB, Lui BG, Tompkins K, Kanevsky I, Muik A, Krumm SA, Guler A, Maddur MS, Walzer KC, Witzel S, Vascotto F, Stanganello E, Ota-Setlik A, Cottingham KJ, Allbritton O, Keverne J, Aragao-Santiago L, Swanson KA, Tureci O, Sahin U. Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination. NPJ Vaccines. 2026 Jan 13;11(1):10. doi: 10.1038/s41541-025-01365-w.

Drugs

Indications